Posts

Posted on

Community Trust Bancorp, Inc. Announces Planned Retirement of Bank President

Community Trust Bancorp, Inc. Announces Planned Retirement of Bank President

PIKEVILLE, Ky.–(BUSINESS WIRE)–
On April 29, 2026, Richard W. Newsom, Executive Vice President of Community Trust Bancorp, Inc. (the “Company”), notified the Company of his planned retirement effective as of February 5, 2027.

Mr. Newsom currently serves and will continue to serve as Executive Vice President of the Company and President of Community Trust Bank, Inc., the Company’s wholly owned bank subsidiary, until his planned retirement on February 5, 2027.

Community Trust Bancorp, Inc., with assets of $6.7 billion, is headquartered in Pikeville, Kentucky and has 69 banking locations across eastern, northeastern, central, and south central Kentucky, six banking locations in southern West Virginia, three banking locations in northeastern Tennessee, four trust offices across Kentucky, and one trust office in Tennessee.

FOR ADDITIONAL INFORMATION PLEASE CONTACT MARK A. GOOCH, CHAIRMAN, PRESIDENT AND CEO, COMMUNITY TRUST BANCORP, INC. AT (606) 437-3229.

KEYWORDS: Kentucky United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on

SKYX Selected to Participate in Inaugural Curated Group of 8 Emerging Companies at the 31st Annual Sohn Investment Conference on May 12, 2026, at Jazz at Lincoln Center in New York City

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), an award winning highly disruptive advanced smart home and AI platform technology company with over 100 U.S. and global pending and issued patents and a portfolio of 60 lighting and home décor websites, with a mission to make homes and buildings become advanced-safe-smart instantly as the new standard, today announced it has been selected to participate in the inaugural Emerging Company Pavilion at the prestigious Sohn Investment Conference 2026, taking place on May 12, 2026 at Jazz at Lincoln Center in New York City.

The Sohn Conference Foundation hosts the annual conference, which brings together over 1,000 leading institutional investors, hedge funds, family offices, and industry operators for a full day of high-conviction investment ideas, dedicated to support pediatric cancer research through the Sohn Conference Foundation, funding groundbreaking research and state-of-the-art technologies.

SKYX has been selected as part of a curated group of only 8 emerging companies.

The Emerging Company Pavilion is designed to provide high-growth potential public companies with direct exposure to a concentrated and influential investor audience in a single-day format.

Selective Participation Highlights SKYX Growth, Market Positioning and Opportunity

Participation in the Emerging Company Pavilion is based on a selection process, including evaluation of:

  • Market capitalization profile
  • Revenue growth trajectory and momentum
  • Strategic alignment with institutional investor interests

According to conference organizers, sectors generating the highest investor demand for 2026 include biotech, artificial intelligence, and financial services, along with a select group of differentiated companies across other sectors demonstrating strong growth characteristics and innovation.

Management Commentary

Rani Kohen, Founder and Executive Chairman, of SKYX Platforms said; “We are honored to be selected to participate in the inaugural Emerging Company Pavilion at the Sohn Conference.”

Lenny Sokolow, CEO of SKYX Platforms said; “This recognition reflects our strong growth trajectory, expanding revenue base, and the increasing demand for our advanced electrical and smart technology solutions. We believe this event provides a unique opportunity to engage with a highly sophisticated investor audience and further broaden awareness of SKYX’s long-term value proposition.”

Event Participation

Members of SKYX’s management team will be available throughout the day at the Emerging Company Pavilion to meet with institutional investors and discuss:

  • The Company’s proprietary advanced smart platform and AI platform
  • U.S. and global market expansion and standardization opportunities
  • Strategic partnerships and commercialization initiatives
  • Long-term growth and revenue outlook

About The Sohn Conference Foundation

The Sohn Conference Foundation brings together the most successful investors from the across the country and around the world, to connect and learn through our conferences, all of which support children’s health programs and life outcomes. The Sohn Conference Foundation honors the memory of Ira Sohn, a talented Wall Street professional whose life was cut short when he passed away from cancer at the age of 29. Ira’s friends and family founded The Sohn Conference Foundation in New York City in 1995. Since then, investment leaders from across the globe have been inspired to launch partner Sohn conferences and unite the financial community to support several charitable causes. To date, The Sohn Conference Foundation has raised more than $150 million. More information on The Sohn Conference Foundation is available at sohnconference.org.

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://www.skyx.com/ or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s ability to achieve positive cash flows; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Investor Relations Contacts:

Jeff Ramson
PCG Advisory
[email protected]

Ronald A. Both
Encore Investor Relations
[email protected]



Posted on

Ruger and Beretta Holding S.A. Announce Strategic Cooperation Agreement

Ruger and Beretta Holding S.A. Announce Strategic Cooperation Agreement

Agreement Reflects Mutual Commitment to Long-Term Value Creation & Stability

Ruger to Increase Beretta Holding Ownership Cap to 25% of the Company

Ruger to Grant Beretta Holding the Ability to Nominate Up to Two Independent Board Members

MAYODAN, N.C.–(BUSINESS WIRE)–Sturm, Ruger & Company, Inc. (NYSE: RGR) (“Ruger” or the “Company”) today announced that it has entered a Strategic Cooperation Agreement (“Agreement”) with Beretta Holding S.A. (“Beretta Holding”), the Company’s largest shareholder. The Agreement reflects a shared commitment to long-term value creation, constructive engagement, and stability for Ruger’s shareholders, employees, customers and industry partners.

Under the terms of the Agreement, Ruger is expected to allow Beretta Holding to increase its investment to up to 25% of the Company’s outstanding shares. The minimum partial tender offer price shall be $44.80 per share in cash – which represents a ~20% premium to the Company’s 60-day volume-weighted average share price prior to Beretta Holding’s tender offer announcement. Such tender offer has not yet commenced and will be subject to applicable regulatory approvals.

In connection with this increased investment, Beretta Holding will have the right to nominate up to two independent directors following the 2026 Annual Meeting of Shareholders and regulatory approval. At that time, the Company will temporarily expand the Board. The nominees will be subject to Ruger’s Nominating and Governance Committee process and qualification criteria.

As part of the agreement, Beretta Holding has committed to a three-year standstill, during which it will not, among other things, initiate or support any proxy contest or similar action. Over that period, Beretta Holding will also vote its shares in alignment with the Ruger Board’s recommendations on all matters (except in cases where leading independent proxy advisory firms, ISS or Glass Lewis, issue an adverse recommendation or in certain extraordinary transactions not involving Beretta Holding).

Additionally, Beretta Holding has withdrawn its director nominations for the 2026 Annual Meeting of Shareholders and only Ruger Board-recommended candidates will be up for election at the meeting.

These provisions, together with other provisions in the Agreement, are designed to safeguard Ruger’s independence and stability while increasing alignment of Beretta Holding with all shareholder interests.

“This agreement is strategically valuable and will benefit all Ruger stakeholders,” said John Cosentino, Chairman of the Board of Ruger. “As a Board, our responsibility and duty is to act in the best interests of all shareholders. This agreement provides stability, avoids further expense and distraction, and creates a framework for productive engagement with Beretta Holding while preserving Ruger’s independence and governance standards.”

The Agreement is positive for Ruger and its shareholders and enables Ruger and Beretta Holding to explore avenues for commercial cooperation in a manner that complies with all applicable laws. Importantly, Ruger will remain an independent U.S. public company – preserving its brand, heritage and strategic direction – while benefiting from Beretta Holding’s admirable legacy and global industry leadership.

“We are pleased to have reached this Agreement with Ruger. This cooperation is fully aligned with the Group’s strategy to further strengthen our presence in the United States, a key market where we have been active for several decades, and it reflects our commitment to continued long‑term development,” said Dott. Pietro Gussalli Beretta, Chairman and CEO of Beretta Holding. “We are eager to work with the Company toward our shared goal of strengthening execution and positioning Ruger for value creation.”

Further information regarding the Agreement, and a copy of the Agreement, will be made available in a Current Report on Form 8-K to be filed by the Company with the United States Securities and Exchange Commission.

About Ruger Firearms

Sturm, Ruger & Co., Inc. is one of the nation’s leading manufacturers of rugged, reliable firearms for the commercial sporting market. With products made in America, Ruger offers consumers almost 800 variations of more than 40 product lines, across the Ruger, Marlin and Glenfield brands. For over 75 years, Sturm, Ruger & Co., Inc. has been a model of corporate and community responsibility. Our motto, “Arms Makers for Responsible Citizens®,” echoes our commitment to these principles as we work hard to deliver quality and innovative firearms.

About Beretta Holding S.A.

With roots dating back to 1526, Beretta Holding is a global family-owned industrial group operating through more than 50 subsidiaries and over 20 internationally recognized brands, with a strong manufacturing footprint in Europe and the United States supporting defense, law enforcement, hunting and shooting sports markets.

Cautionary Note Regarding Forward Looking Statements

Certain statements in this communication may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “may,” “will,” “could,” “anticipate,” “estimate,” “expect,” “predict,” “project,” “future,” “potential,” “intend,” “plan,” “assume,” “believe,” “forecast,” “look,” “build,” “focus,” “create,” “work,” “continue” or the negative of such terms or other variations thereof and words and terms of similar substance. Such statements also include, among others, statements with respect to the future performance of the Company, statements with respect to the potential future commencement of a tender offer (and on what timing and terms), statements with respect to the performance of Ruger and Beretta Holding of their respective obligations pursuant to the Agreement and statements with respect to whether any regulatory approvals referred to herein will be received and if so on what terms and timing. The forward-looking statements in this communication are based upon the current beliefs, assumptions and expectations of Ruger and are subject to significant risks and uncertainties, including without limitation, market demand, sales levels of firearms, anticipated castings sales and earnings, the need for external financing for operations or capital expenditures, the results of pending litigation against Ruger, the impact of future firearms control, environmental legislation and accounting estimates and the performance by Ruger and Beretta Holding of their respective obligations pursuant to the Agreement (and, with respect to any regulatory approvals, any matters related to Beretta Holding or its related persons), any one or more of which could cause actual results to differ materially from those projected. Actual results could differ materially from those expressed in or implied by the forward-looking statements contained herein because of a variety of other factors, including without limitation those detailed in the Ruger’s annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings made by Ruger with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. Ruger expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in beliefs, assumptions or expectations or any change in events, conditions or circumstances on which any such statements are based.

Important Information and Where to Find It

Ruger has filed a definitive proxy statement and proxy card with the SEC in connection with its solicitation of proxies from the Company’s stockholders for Ruger’s 2026 Annual Meeting of Stockholders (the “Proxy Statement”). This press release is not a substitute for such proxy statement. RUGER STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) FILED BY RUGER AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Stockholders may obtain copies of these documents and other documents filed with the SEC by Ruger free of charge through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Ruger are also available free of charge by accessing the “Corporate” section of the Company’s website at www.ruger.com/corporate.

The tender offer described in this press release has not commenced. This press release is for informational purposes only and is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell shares of the Company, nor is it a substitute for any tender offer materials that Beretta Holding or the Company will be required to file with the SEC if the tender offer commences. If the tender offer is commenced, Beretta Holding will be required to file a Tender Offer Statement on Schedule TO with the SEC, and the Company will be required to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE COMPANY’S SECURITY HOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING ANY OFFER TO PURCHASE, RELATED LETTER OF TRANSMITTAL AND ANY OTHER TENDER OFFER DOCUMENTS) AND THE COMPANY’S SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING WHETHER TO TENDER THEIR SHARES INTO THE TENDER OFFER, IF THE TENDER OFFER COMMENCES. IF THE TENDER OFFER IS COMMENCED, BERETTA HOLDING’S TENDER OFFER STATEMENT ON SCHEDULE TO (INCLUDING THE RELATED EXHIBITS) AND THE COMPANY’S SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEBSITE AT WWW.SEC.GOV. IN ADDITION, IF THE TENDER OFFER IS COMMENCED, (I) THE TENDER OFFER MATERIALS THAT ARE FILED BY BERETTA HOLDING WITH THE SEC WILL BE MADE AVAILABLE TO ALL STOCKHOLDERS OF THE COMPANY FREE OF CHARGE FROM THE INFORMATION AGENT FOR THE TENDER OFFER AND (II) THE COMPANY’S SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL BE MADE AVAILABLE TO ALL STOCKHOLDERS OF THE COMPANY FREE OF CHARGE BY THE COMPANY.

Certain Information Regarding Participants

Ruger and its directors and certain of its executive officers are deemed to be “participants” (as defined in Schedule 14A under the Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s stockholders by Ruger in connection with the matters to be considered at Ruger’s 2026 Annual Meeting of Stockholders. Information regarding the names of Ruger’s executive officers and directors and their respective interests in Ruger by security holdings or otherwise is set forth in Ruger’s definitive Proxy Statement for the 2026 Annual Meeting of Stockholders, which was filed with the SEC on April 27, 2026, which is available here, including under the headings “Proposal No. 1 – Election of Directors”, “Director Nominees”, “The Board of Directors, its Committees and Policies”, “Committees of the Board”, “Director Compensation”, “Beneficial Ownership Of Directors And Management Table”, “Certain Relationships And Related-Party Transactions”, “Proposal No. 3 – Advisory Vote on Compensation of Named Executive Officers”, “Compensation Discussion and Analysis”, “Executive Compensation”, “Potential Payments Upon Termination Or Change In Control”, “Potential And Actual Payments Under Severance Agreements Table”, “Pension Plans”, “Chief Executive Officer Pay Ratio”, “Pay Versus Performance (PVP)” and “Annex B – Supplemental Information Regarding Participants in the Solicitation”. To the extent holdings of such persons in the Company’s securities change following the amounts described in the definitive Proxy Statement, such changes will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. These documents, including the definitive Proxy Statement (and any amendments or supplements thereto) and other documents filed by the Company with the SEC, are or will be available free of charge at the SEC’s website at www.sec.gov. Copies of the documents filed by Ruger are also available free of charge by accessing the “Corporate” section of the Company’s website at www.ruger.com/corporate.

For further information, contact:

Ruger: Rob Werkmeister, Senior Vice President of Marketing & Customer Experience

[email protected]

Beretta Holding: Longacre Square Partners

[email protected] / [email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Retail Sports Other Retail Other Sports Specialty Hunting

MEDIA:

Logo
Logo
Posted on

FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM

Maranello (Italy), May 4, 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on April 10, 2026, as the second tranche of the multi-year share buyback program of approximately Euro 3.5 billion expected to be executed by 2030 in line with the disclosure made during the 2025 Capital Markets Day (the “Second Tranche”), the additional common shares – reported in aggregate form, on a daily basis on the Euronext Milan (EXM) as follows:

Trading

Date

(dd/mm/yyyy)

Stock Exchange

Number of common shares purchased

Average price per share


excluding fees


(€)

Consideration

excluding fees

(€)
27/04/2026 EXM 14,000 297.8245 4,169,543.00
28/04/2026 EXM 12,279 294.0352 3,610,458.22
29/04/2026 EXM 14,000 289.4002 4,051,602.80
30/04/2026 EXM 4,503 286.9505 1,292,138.10
Total – 44,782 293.0584 13,123,742.12

        
Since the announcement of such Second Tranche till May 1, 2026, the total invested consideration has been:

  • Euro 42,799,547.81 for No. 141,819 common shares purchased on the EXM

As of May 1, 2026 the Company held in treasury No. 17,561,490 common shares, net of shares assigned under the Company’s equity incentive plan, corresponding to 9.06% of the then total issued common shares. Including the special voting shares, the Company held in treasury 9.42% of the then total issued share capital. For the avoidance of doubt, the cancellation of treasury shares, as approved by the Annual General Meeting of Shareholders of the Company held on April 15, 2026, has not yet been effectuated and therefore has not been taken into account for such calculations.

Since January 5, 2026, start date of the multi-year share buyback program of approximately Euro 3.5 billion announced during the 2025 Capital Markets Day, until May 1, 2026, the Company has purchased a total of 1,027,264 own common shares on EXM and NYSE, including transactions for Sell to Cover, for a total consideration of Euro 303,557,632.86.

A comprehensive overview of the transactions carried out under the buyback program, as well as the details of the above transactions, are available on Ferrari’s corporate website under the Buyback Programs section (https://www.ferrari.com/en-EN/corporate/buyback-programs).

For further information:
Media Relations
Email: [email protected]

Attachment



Posted on

SentinelOne’s 2026 PartnerOne Awards Recognize Partners Shaping the Future of AI Security

SentinelOne’s 2026 PartnerOne Awards Recognize Partners Shaping the Future of AI Security

CORAL GABLES, Fla.–(BUSINESS WIRE)–SentinelOne® (NYSE: S), the AI Security leader, today announced the winners of the 2026 North American PartnerOne Awards, recognizing outstanding contributions to innovation in AI and security solutions among its partners across the United States and Canada. The awards were presented during the company’s annual PartnerOne Summit, where more than 150 strategic partners gathered to explore how security in the era of AI is transforming protection for enterprise customers in partnership with SentinelOne.

“Our partners are at the center of redefining cybersecurity in the age of AI. As the industry shifts toward AI-native security, our partners are leading that transformation alongside us,” said Brian Lanigan, SVP, Head of Global Partner Ecosystem at SentinelOne. “As the threat landscape evolves, the synergy between our AI-powered innovations and our partners’ strategic vision is vital. Together, we’re not just responding to the threat landscape—we’re shaping the future of cybersecurity.”

SentinelOne’s global partner network is central to delivering a decisive security advantage for customers worldwide. Backed by the company’s pioneering AI-driven technology, SentinelOne’s global partner network empowers organizations to navigate an increasingly volatile digital environment with confidence. This year’s honors reflect a shared dedication to technical excellence and a proven track record of delivering superior protection and ROI for customers worldwide.

The 2026 NAM PartnerOne Award Winners include:

  • 2026 SentinelOne Vision Partner of the Year– Guidepoint Security

  • 2026 SentinelOne Partner of the Year – CDW

  • 2026 Canadian Partner of the Year – Mobia

  • 2026 LATAM Partner of the Year – RAN Security

  • 2026 Momentum Award – ePlus

  • 2026 Distributor of the Year – Ingram Micro

  • 2026 Technical Star Award – Bill Wheeler, ePlus

  • 2026 STP Partner of the Year – Cloudflare

  • 2026 Cloud Partner of the Year – AWS

  • 2026 IR Partner of the Year – Arete

  • 2026 Managed Service Provider of the Year – LevelBlue

The Award Winners in Their Words

“Being recognized as a SentinelOne PartnerOne Award winner is a testament to the strength of our collaboration and the results we’re delivering for clients around the world. Together, we’re combining advanced AI-driven technology with elite managed security expertise to help organizations detect, respond, and recover with greater speed and confidence. We’re proud of what we’ve accomplished together and excited for what’s ahead.” – Bob McCullen, Chairman and CEO of LevelBlue.

“We’re honored to receive SentinelOne’s PartnerOne Cloud Partner of the Year Award, a recognition that reflects the shared commitment our collaboration brings to helping customers protect their cloud environments and respond to threats with greater speed and confidence. Together with SentinelOne, we’re delivering generative AI-driven security solutions and automated response capabilities that give customers the real-time visibility and autonomous defense they need to operate securely at scale.” – Chris Grusz, Managing Director, Technology Partnerships, AWS.

“We’re proud to be named a SentinelOne PartnerOne Award winner. SentinelOne continues to push the boundaries of AI-native, autonomous security, and together we’re helping organizations strengthen their defenses and respond to threats faster. This recognition underscores the power of our partnership and the results we’re delivering for our customers.” – Mark Thornberry, SVP of Partnerships, GuidePoint Security.

“It’s great to be recognized by SentinelOne. This speaks to the strong working relationship between our teams and the focus we share on helping customers stay ahead of an evolving threat landscape.” – Ashif Samnani, Principal of Cybersecurity, MOBIA.

To learn more about SentinelOne’s global partners and the value they can deliver, click here.

About SentinelOne

SentinelOne (NYSE: S) is the leader in AI security, setting the standard for using AI and automation to give defenders a decisive operating advantage. Built for those who secure our world, its platform delivers unified coverage across endpoints, identity, cloud, and AI. Powered by Autonomous Security Intelligence, SentinelOne stops attacks at machine speed, reducing risk and delivering clarity and control to stay one step ahead. Headquartered in Mountain View, California with teams worldwide, SentinelOne protects nearly one-fifth of the Fortune 500 and hundreds of Global 2000 enterprises. From Main Street to Wall Street, the world’s most critical organizations trust SentinelOne with their security.

Third-Party Trademark Disclaimer:

All third-party product names, logos, and brands mentioned in this publication are the property of their respective owners and are for identification purposes only. Use of these names, logos, and brands does not imply affiliation, endorsement, sponsorship, or association with the third-party.

Media Contact:

Josh Swarz

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Artificial Intelligence Internet

MEDIA:

Logo
Logo
Posted on

Earth’s Best Debuts All-New Organic Snacks Made Just for Big Kids

New Organic Crispy Sticks and Veggie Waves Deliver Bold Flavor, Wholesome Ingredients, and Better-for-You Fuel for Growing Kids Ages 4 to 8.

HOBOKEN, N.J., May 04, 2026 (GLOBE NEWSWIRE) — Earth’s Best®, a trusted brand of organic foods for babies and kids to grow with, is proud to introduce its first line of organic snacks created specifically for kids ages 4 to 8 years old: Earth’s Best Big Kids Snacks. Launching nationwide this spring, the portfolio includes Organic Crispy Sticks and Organic Veggie Waves — delicious snacks packed with bold flavor and ingredients that help fuel growing kids and all their big adventures.

For decades, Earth’s Best has supported families through every feeding stage. Now, as little ones enter their “big kid” years — complete with backpacks, sports, playdates, independence, and bigger appetites — many caregivers find that the better-for-you snack options they relied on start to disappear. Big Kids Snacks offer fun, irresistible flavors packed with nutritious, wholesome, organic ingredients, making snack time something kids love and parents can feel confident about.

“At Earth’s Best, we know families want snacks they can trust as their kids grow,” said Pamela Goldberg, Chief Marketing Officer at Earth’s Best. “Big Kids Snacks are the next natural evolution in our mission to support families at every age and stage. They’re packed with flavor, wholesome ingredients, and just the right fuel to keep up with busy days or snack-time fun. From first bites and self-feeding milestones to lunch boxes and backpacks, we’re here to make snacking simple, enjoyable, and something caregivers can feel good about.”

Introducing Earth’s Best Big Kids Snacks:

  • Earth’s Best® Organic Crispy Sticks, crunchy baked (not fried) sticks made with organic lentils and real cheese, offer a wholesome, flavorful option for growing kids with bigger appetites. Crispy Sticks deliver a satisfying crunch in two bold varieties, Cheesy Mac and Pizza, perfect for lunch boxes, after‑school snacking, and on‑the‑go moments.
  • Earth’s Best® Organic Veggie Waves are wavy snacks with a veggie‑forward taste made with organic peas and sorghum. Baked, not fried, with protein, Veggie Waves offer big flavor and better‑for‑you ingredients in two delicious options, Rock’n Ranch and BBQ Blast, giving kids a fun, crunchy way to enjoy snacks throughout the day.

All Earth’s Best Big Kids Snacks are certified USDA Organic, non‑GMO, and made without artificial flavors or artificial preservatives. Earth’s Best Big Kids Snacks began rolling out nationwide in April 2026 at major retailers, including Target and Walmart. Products will be available in both multiserve and single‑serve multipack formats.

Meet Our Family Feeding and Snack Experts

Transitioning to school-age, lunch box and backpack snacking comes with its own sets of excitement, questions, and sometimes challenges for caregivers. To provide support and practical tips alongside the launch of Big Kids Snacks, while being a trusted resource for Earth’s Best products tailored to every feeding stage and journey, Earth’s Best has partnered with two leading experts in pediatric health and nutrition:

  • Whitney Casares, M.D., MPH, FAAP, is a board-certified pediatrician, author, and founder of Modern Mommy Doc whose clinical expertise and family-focused approach help caregivers raise emotionally and physically healthy kids with confidence.
  • Joy Dubost, Ph.D., R.D., is a registered dietitian and food scientist with over 20 years of experience across the food industry, is the founder of NJOY Health & Nutrition and has a passion for supporting transparent, science-backed nutrition for little ones and families, a commitment she brings to her work with Earth’s Best.

Together, they bring thoughtful expertise to Earth’s Best’s mission of supporting kids and their caregivers at every age and stage. Through these partnerships, Earth’s Best will provide families with trusted, science-backed guidance, serving as a consistent resource as their children grow.

For more information on the Earth’s Best Big Kids Snacks launch or family feeding expertise, visit www.earthsbest.com or follow Earth’s Best on Instagram @earthsbest.

About Earth’s Best®

Earth’s Best® was founded in 1985 and pioneered organic baby foods within the mainstream market. For 40 years, Earth’s Best has been a trusted leader in organic foods for babies and kids to grow with, providing a wide range of nutritious options — from formula and baby food to self-feeding snacks and toddler meals. The brand’s mission is to make wholesome, tasty food fun for children while helping families navigate the early years of feeding.

About the Hain Celestial Group

Hain Celestial Group (Nasdaq: HAIN) is a leading health and wellness company whose purpose is to inspire healthier living for people, communities, and the planet through better-for-you brands. For more than 30 years, Hain has focused on delivering nutrition and well-being that positively impact today and tomorrow. Headquartered in Hoboken, New Jersey, Hain Celestial’s products, across baby/kids, beverages, meal preparation, and personal care, are marketed and sold in over 70 countries around the world. Our leading brands include Hartley’s® jelly, Earth’s Best® and Ella’s Kitchen® baby and kids foods, Celestial Seasonings® teas, Joya® and Natumi® plant-based beverages, Greek Gods® yogurt, Cully & Sully®, Yorkshire Provender®, New Covent Garden®, and Imagine® soups, Linda McCartney’s® (under license) meat-free, and Avalon Organics® personal care, among others. For more information, visit hain.com and LinkedIn.

Media Contact:

Justin Godley
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/31d3302e-747c-4be6-9b39-afd378a04af8



Posted on

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Monday, May 11, 2026, starting at 5:00 p.m. Eastern Standard Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register-conf.media-server.com/register/BI717266b2e2e943cb92bb04def907b571.

Webcast: https://edge.media-server.com/mmc/p/orxawzr2.

The press release with the first quarter 2026 financial results and related materials will be available at https://investors.coherus.com before the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at https://investors.coherus.com/events-presentations.

Please dial in15 minutes early to ensure a timely connection to the call.

Disclosure Information

Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

About Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships.

Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.

LOQTORZI® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.

Coherus Oncology Contact Information:

For Investors:

Carrie Graham
Vice President, Investor Relations & Advocacy
[email protected]



Posted on

Intel Announces Leadership Appointments to Advance Client Computing and Enable Future Innovation

Intel Announces Leadership Appointments to Advance Client Computing and Enable Future Innovation

NEWS HIGHLIGHTS

  • Intel appoints Alex Katouzian as executive vice president and general manager of Client Computing & Physical AI

  • Names Pushkar Ranade chief technology officer

SANTA CLARA, Calif.–(BUSINESS WIRE)–
Intel Corporation (NASDAQ: INTC) today announced two key leadership appointments to strengthen its core product business and advance the company’s innovation agenda.

Alex Katouzian Appointed to Lead Client Computing & Physical AI Group

Alex Katouzian will join Intel as executive vice president and general manager of the Client Computing and Physical AI Group. In this role, Katouzian will align Intel’s client computing business with emerging physical AI systems that span robotics, autonomous machines, and other AI devices.

“AI is creating unprecedented opportunities at the edge, driving a sea change in client computing and physical AI systems,” said Lip-Bu Tan, Intel CEO. “Alex brings deep technical expertise, strong operational discipline, and decades of experience building and scaling global compute platforms. He is the right leader to help us reimagine client computing beyond the traditional PC and align this future with the next wave of growth in physical AI.”

Katouzian joins Intel from Qualcomm Technologies where he most recently served as executive vice president and group general manager of mobile, compute, and extended reality (XR). He is widely recognized for his technical vision and consistent track record of execution at scale.

“Intel is creating the foundation for AI-driven transformation, from leading in AI PCs, to scaling AI inference at the edge, and accelerating the future of physical AI systems,” said Katouzian. “I’m excited to join Lip-Bu and the Intel team at this critical moment to help scale innovation and deliver the next generation of computing experiences.”

Katouzian will join Intel in May.

Pushkar Ranade Appointed Chief Technology Officer

Intel also announced that Pushkar Ranade has been appointed chief technology officer, transitioning from the interim role. As CTO, Ranade will advance the company’s technology strategy, lead special technology projects, and drive the development of critical emerging areas, including quantum computing, neuromorphic computing, photonics, and novel materials.

Ranade will continue to serve as chief of staff to the CEO, ensuring strong alignment between Intel’s technology strategy and business priorities.

Both Katouzian and Ranade will report directly to CEO Lip-Bu Tan.

About Intel

Intel (Nasdaq: INTC) designs and manufactures advanced semiconductors that connect and power the modern world. Every day, our engineers create new technologies that enhance and shape the future of computing to enable new possibilities for every customer we serve. Learn more at intel.com.

Intel Media Relations

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Semiconductor Hardware Robotics Technology Artificial Intelligence

MEDIA:

Logo
Logo
Posted on

CrowdStrike Named a Leader in the Inaugural 2026 Gartner® Magic Quadrant™ for Cyberthreat Intelligence Technologies

CrowdStrike Named a Leader in the Inaugural 2026 Gartner® Magic Quadrant™ for Cyberthreat Intelligence Technologies

CrowdStrike positioned furthest right for Completeness of Vision among all vendors evaluated

AUSTIN, Texas–(BUSINESS WIRE)–CrowdStrike (NASDAQ: CRWD) today announced it has been named a Leader in the inaugural 2026 Gartner® Magic Quadrant™ for Cyberthreat Intelligence Technologies1. CrowdStrike positioned furthest right for Completeness of Vision among all vendors evaluated. As adversaries weaponize AI to collapse the defender’s window of response, CrowdStrike transforms threat intelligence into agentic adversary disruption, delivering intelligence at the point of decision-making, at the speed of the threat.

“CrowdStrike pioneered adversary-driven intelligence, using frontline findings to stop real-world attacks,” said Adam Meyers, head of counter adversary operations at CrowdStrike. “By combining the industry’s deepest understanding of adversary operations with agentic systems that reason across threat data and exposure risk, hunt adversaries proactively, and take decisive action across the kill chain, CrowdStrike accelerates outcomes and stops breaches.”

From Static Threat Intel Reports to Agentic Adversary Disruption

CrowdStrike sets the industry standard for adversary intelligence, tracking over 280 of the world’s most sophisticated nation-state, eCrime and hacktivist groups. In our view, the Gartner inaugural report based on the Cyberthreat Intelligence category confirms what adversary behavior has already made clear: threat intelligence is no longer a reporting discipline, it is an operational one. CrowdStrike’s agentic threat intelligence drives a market transformation, delivering agents that reason across adversary behavior, hunt proactively, and disrupt attacks across the kill chain at machine speed.

Threat AI, the industry’s first agentic threat intelligence system, reasons across threat data, hunts adversaries proactively, and takes decisive action across the kill chain, pursuing and disrupting adversaries at machine speed and accelerating threat response at the speed of the AI-enabled adversary. CrowdStrike’s expanding fleet of AI agents transforms finished intelligence into agentic adversary disruption, exposing adversary tradecraft and closing critical gaps at the speed of the adversary.

The CrowdStrike Falcon® platform brings detection and response, intelligence, and exposure management together in one platform. The same data used to detect a threat informs the agentic intelligence that explains it, identifies exposed assets and attack paths, and helps organizations operationalize Continuous Threat Exposure Management (CTEM) as part of adversary-driven defense, disrupting the adversary without handoff.

CrowdStrike’s Threat Intelligence & Hunting capabilities are continuously informed by real-world decisions from CrowdStrike Counter Adversary Operations’ team of elite threat hunters and intelligence experts. Powered by trillions of daily security events and industry-leading expertise, the Falcon platform operationalizes agentic threat intelligence at scale, connecting external threat activity to internal exposure risk and enabling real-time action across SIEM, SOAR, XDR, cloud and SASE environments to stop breaches.

Download the Gartner report to learn more about CrowdStrike’s recognition in the 2026 Gartner® Magic Quadrant™ for Cyberthreat Intelligence Technologies.

Gartner and Magic Quadrant are trademarks of Gartner, Inc. and/or its affiliates. Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

About CrowdStrike

CrowdStrike (NASDAQ: CRWD), a global cybersecurity leader, has redefined modern security with the world’s most advanced cloud-native platform for protecting critical areas of enterprise risk – endpoints and cloud workloads, identity and data.

Powered by the CrowdStrike Security Cloud and world-class AI, the CrowdStrike Falcon® platform leverages real-time indicators of attack, threat intelligence, evolving adversary tradecraft, and enriched telemetry from across the enterprise to deliver hyper-accurate detections, automated protection and remediation, elite threat hunting, and prioritized observability of vulnerabilities.

Purpose-built in the cloud with a single lightweight-agent architecture, the Falcon platform delivers rapid and scalable deployment, superior protection and performance, reduced complexity, and immediate time-to-value.

CrowdStrike: We stop breaches.

Learn more: https://www.crowdstrike.com/

Follow us: Blog | X | LinkedIn | Instagram

Start a free trial today: https://www.crowdstrike.com/trial

© 2026 CrowdStrike, Inc. All rights reserved. CrowdStrike and CrowdStrike Falcon are marks owned by CrowdStrike, Inc. and are registered in the United States and other countries. CrowdStrike owns other trademarks and service marks and may use the brands of third parties to identify their products and services.

1Gartner, 2026 Gartner® Magic Quadrant™ for Cyberthreat Intelligence Technologies, Jonathan Nunez, Jaime Anderson, Carlos De Sola Caraballo,May 4, 2026.

Media Contact

Jake Schuster

CrowdStrike Corporate Communications

[email protected]

KEYWORDS: California Texas United States North America

INDUSTRY KEYWORDS: Networks Internet Security Technology Software

MEDIA:

Logo
Logo
Posted on

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026

– 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT® in pancreatic adenocarcinoma –

– Favorable safety profile observed, with only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks in some of the most challenging, heavily pre-treated patients in oncology –

– Highly heterogeneous patient population for whom available options are extremely limited included patients ineligible for chemotherapy as well as patients who had received up to four prior lines of chemotherapy –

– Streamlined outpatient endoscopic ultrasound (EUS)-guided procedure designed for seamless integration into standard GI endoscopy workflow –

– Results shared in oral presentation at DDW 2026, the first presentation of Alpha DaRT at a premier international gastroenterology conference –

JERUSALEM, May 04, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced the presentation of updated pooled results from two first-in-human clinical trials of Alpha DaRT in pancreatic ductal adenocarcinoma (PDAC) at Digestive Disease Week (DDW) 2026, the world’s premier international gastroenterology conference.

The abstract, entitled “Updated Results of Feasibility, Safety, and Tumor Control in Two First-In-Human Trials of a Novel Alpha-Emitting Radionuclide for Pancreatic Adenocarcinoma,” was selected for podium presentation in the Pancreatic Cancer I: Diagnosis and Treatment session. The abstract is based on combined data from two clinical protocols conducted at Hadassah Medical Center in Jerusalem, Israel, and was presented by Philip Blumenfeld, MD, Director of Advanced Radiotherapy Unit, Sharett Institute of Oncology, Hadassah Medical Center. This marks the first time that Alpha DaRT clinical results have been selected for oral presentation at a major gastroenterology conference.

Clinical Results

The results were pooled from two clinical studies of Alpha DaRT treating localized unresectable and metastatic pancreatic cancers in a heterogeneous patient population, including those who were ineligible to receive chemotherapy as well as those who had undergone up to four prior lines of chemotherapy. Despite this breadth and complexity of clinical backgrounds, 100% local disease control was achieved across all 19 evaluable patients based on modified RECIST v1.1 criteria, as measured by best overall response, reflecting 15 (79%) with stable disease and 4 (21%) with partial response, a landmark result underscoring the potential of Alpha DaRT as a compelling intratumoral treatment regardless of prior treatment history.

The safety profile was also highly encouraging. Among 26 subjects treated, only 8 device-associated adverse events were observed in 7 subjects (27%), all of which resolved within two weeks, with the exception of one instance of lingering fatigue.

Uzi Sofer, CEO of Alpha Tau, stated: “These results represent a highly significant milestone for Alpha DaRT and for Alpha Tau’s strategic mission to establish intratumoral alpha-emitting radiotherapeutics as a meaningful option in oncology’s most challenging indications. What makes these data particularly compelling is not only the efficacy and safety signal – which are both exceptional – but also the fact that this treatment was designed to integrate naturally into the existing patient pathway and GI workflow. The ability to deliver Alpha DaRT via EUS, a procedure which gastroenterologists already perform routinely, makes this treatment highly attractive from a clinical adoption perspective. Furthermore, the combination of a localized treatment with systemic approaches represents a major advantage over combinations of other systemic therapies with chemotherapy regimens, which often carry significant toxicity burdens. We believe Alpha DaRT has the potential to fundamentally change how pancreatic cancer is treated, and these results bring us closer to realizing that potential.”

“These are some of the most challenging, heavily pre-treated patients in oncology – patients for whom available options are extremely limited,” commented Robert Den, MD, Chief Medical Officer of Alpha Tau. “Nevertheless, consistency of response across such a diverse cohort is a powerful signal of Alpha DaRT’s potential. Coupled with a very promising safety profile characterized by low rates of device-associated adverse events and rapid resolution, these results provide a strong foundation for the advancement of Alpha DaRT in pancreatic cancer and further reinforce the scientific basis for our ongoing U.S. multicenter pancreatic cancer IMPACT trial.”

Philip Blumenfeld, MD, Director of Advanced Radiotherapy Unit, Sharett Institute of Oncology, Hadassah Medical Center, and presenter of the abstract, commented: “As a radiation oncologist and member of a multidisciplinary pancreatic cancer team, I see these results as potentially addressing a significant unmet need from several clinical perspectives. Pancreatic cancer has historically been relatively resistant to radiation therapy, and while modern techniques such as SBRT have improved our ability to deliver ablative doses, their use remains constrained by the close proximity of critical gastrointestinal structures. As a result, achieving meaningful local control without toxicity continues to be a major challenge. The ability to deliver intratumoral alpha-particle therapy via EUS, with consistent disease control across treated patients, hopefully represents an important advance in the radiotherapeutic management of this disease. Equally notable is the favorable toxicity profile. In a patient population already heavily burdened by aggressive systemic chemotherapy, a treatment that offers strong local efficacy with minimal added toxicity is highly compelling. This combination makes Alpha DaRT a treatment I am genuinely excited about for my patients.”

About Alpha DaRT

®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. The Alpha DaRT treatment has not been approved in the US for commercialization or for use outside of an approved clinical trial. In addition, any statements or information that refer to the Alpha DaRT treatment in pancreatic cancer patients, including the potential benefits and associated risks, future applications and uses, the IMPACT study and potential indication approvals, are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval to commercialize its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on form 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.

Investor Relations Contact

[email protected]